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Eleanor M Dinnett1*, Sharon Kean1, Elizabeth P Tolmie2, Elizabeth S Ronald3 and Allan Gaw4Abstract
The implementation of a pharmacovigilance service compliant with the legal and regulatory responsibilities of
clinical trial sponsors presents particular challenges for sponsors in a non-commercial setting.
In this paper we examine these challenges in detail. We identify and discuss the key steps in the development of a
pharmacovigilance service within a public health service and university setting in the United Kingdom. We describe
how we have established a central Pharmacovigilance Office with dedicated staff and resources within our
organisation. This office is supported by an electronic pharmacovigilance reporting infrastructure developed to
facilitate the receipt and processing of safety information, the onward reporting in compliance with legislation
and the provision of sponsor institution oversight of clinical trial participant safety. An education and training
programme has also been set up to ensure that all relevant staff in the organisation are fully aware of the
pharmacovigilance service and are appropriately trained in its use.
We discuss possible alternatives to this approach and why we consider our solution to be the most
appropriate to ensure that a non-commercial sponsor organisation and investigators are operating in a fully
compliant way.
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Background
Pharmacovigilance is defined by the World Health
Organization as the pharmacological science relating to
the detection, assessment, understanding and prevention
of adverse effects, particularly long-term and short-term
side effects, of medicines [1]. In order to comply with
European and UK regulatory requirements these activities
must be carried out for both authorised medicinal pro-
ducts and for those used within a clinical research
programme. Any organisation taking on the role of spon-
sor of clinical trials of investigational medicinal products
(CTIMPs) must put in place arrangements for safety
reporting as part of a pharmacovigilance programme.
Within the pharmaceutical industry, pharmacovigilance
is a major component of clinical trial conduct and att-* Correspondence: eleanor.dinnett@ggc.scot.nhs.uk
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reproduction in any medium, provided the orracts considerable resources. Within the public sector,
pharmacovigilance has in recent years become an equally
important concern especially across the European Union
(EU) member states following the implementation of the
EU Clinical Trials Directive (2001/20/EC) [2] and its
transposition into UK law by The Medicines for Human
Use (Clinical Trials) Regulations 2004 [3] thereby setting
out specific requirements for pharmacovigilance in
CTIMPs. These regulations describe pharmacovigilance as
‘the recording and reporting of adverse events and reac-
tions to medicinal products being used in a clinical trial’
with Regulations 32 to 35 detailing the requirements.
Within the public sector the provision of a phar-
macovigilance service to support clinical trials and to
fulfil the legal and regulatory responsibilities of spon-
sors carries a number of particular challenges largely
because of the limitation of resources and available ex-
pertise. In this paper we examine these challenges in
detail, describe how we have established a robustl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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university setting and discuss the lessons we have learned.
Requirements of a pharmacovigilance service
In order to establish a pharmacovigilance and safety
reporting service it is first necessary to understand the
requirements of such a service. The responsibilities for
pharmacovigilance are laid out within a range of key
documents including the EU Clinical Trials Directive
[2], The Medicines for Human Use (Clinical Trials)
Regulations 2004 [3], ICH-GCP E6 [4] and governance
guidance documents such as the UK Research Governance
Frameworks [5,6].
Most recently these responsibilities have been defined in
a new composite guidance document from the European
Commission [7] as detailed in Table 1.
The responsibilities of the sponsor with respect to
pharmacovigilance and safety reporting are clearly ex-
tensive and can only be fulfilled by creating a robust
reporting system backed up with education, training
and oversight of the process. The challenge is how to
achieve such a system, which will be acceptable to any
auditor or inspector from both the public and private
sectors.
The development of an effective pharmacovigilance ser-
vice in a non-commercial setting is a complex process in-
volving a number of different stakeholders and their
competing agendas and is often built on existing, some-
times piecemeal, services. The development of our service
was to some extent the product of local factors, but much
of what we learned in the process is applicable to others.
We have identified the following seven key steps in the de-
velopment of our service and will discuss each in turn:
1. Get stakeholders together
2. Review existing services
3. Define the process
4. Translate the process into standard operating
procedures
5. Decide how to operationalise these and what
resources are neededTable 1 Summary of safety reporting responsibilities [7]
Investigator responsibilities Sponso
Report serious adverse events to the sponsor as per the protocol Keep d
investig
Report certain non-serious adverse events and/or laboratory
abnormalities to the sponsor as per the protocol
Report
nationa
Inform
Submit
Ethics
Contin
include6. Implement training and education of research staff
7. Maintain oversight
1. Get stakeholders together: An effective
pharmacovigilance service requires input from a
number of key partners in the process. These may
include the local NHS Research and Development
Office, Hospital Pharmacy, local Clinical Research
Facilities, Data Management services and
Universities. To facilitate this interaction a
pharmacovigilance group should be established with
representation from each stakeholder. This group
will serve as the operational committee
implementing and overseeing any new service.
2. Review existing services: The first task of the
pharmacovigilance group is to review any existing
pharmacovigilance and safety reporting services. In
most circumstances clinical research will already be
ongoing in an institution and there may be
departments or even individuals who have already
developed effective systems. Often, however, there
will be no coherent service or any services that do
exist may be fragmentary, specific to individual
studies and perhaps even conflicting. It is
important, however, to recognise examples of good
practice and if possible incorporate them into any
new service.
3. Define the process: Assuming that a new
pharmacovigilance service is required, the next step
is to define the nature of this. While
pharmacovigilance is defined as a requirement in
UK law there is limited guidance on how to fulfil
this responsibility. It is important that the
pharmacovigilance group has expertise in
pharmacovigilance and safety reporting in practice
and should develop, in the first instance, a flow
chart of adverse event reporting and processing that
may be endorsed by the group as a whole. An
example of such a flowchart is shown in Figure 1.r responsibilities
etailed records of all adverse events which are reported by the
ator or investigators
suspected unexpected serious adverse reactions (SUSARs) to the
l competent authority and the Ethics Committee
investigators of SUSARs
an annual safety report to the national competent authority and the
Committee
uously weigh anticipated benefits and risks of the clinical trial which
s ongoing safety evaluation of IMPs
Yes
No
SAE identified at site
SAE report sent to PV  
Office (fax, 
telephone, online)
SAE entered onto PV 
Database
SAE report reviewed by  
PV Officer
QC performed on 
database entry
Database updated
SAE form filed 
Errors found on QC
Manual query created for 
missing/inconsistent data
Manual Query sent to site 
for resolution
Database updated with 
information from resolved 
query
If SAE is a SUSAR, reported 
via eSUSAR to MHRA and 
to REC by email
Report to EudraVigilance if 
not forwarded by National  
Competent Authority
On anniversary of CTA line  
listings and cumulative 
summaries prepared or 
inclusion in DSUR
Reports prepared as 
required for sponsor 
oversight, IDMC
At End of Trial all documentation
archived in line with regulatory 
requirements
Investigators informed
Figure 1 Flowchart of SAE data. CTA, clinical trial authorisation; DSUR, Development safety update report; IDMC, Independent data monitoring
committee; MHRA, Medicines and healthcare products regulatory agency; PV, pharmacovigilance; QC, quality control; REC, Research ethics
committee; SAE, Serious adverse event; SAR, Serious adverse reaction; SUSAR, suspected unexpected serious adverse reaction.
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scale of the operation envisaged and available
resources.
4. Translate the process into standard operating
procedures (SOPs): Once the process has been
agreed, it must be broken down into its component
parts and defined in the form of SOPs. These SOPs
should be signed off and managed in the same way
as all other institutional SOPs.
5. Decide how to operationalise these and what
resources are needed: The pharmacovigilance
process detailed in the SOPs will inevitably require
resources for its implementation. This may involve
the identification and support of specific staff who
will serve as the pharmacovigilance team. It may
also require the identification of space to serve as a
Pharmacovigilance Office. Alternatively, some
institutions will effectively delegate much of the
delivery of pharmacovigilance activities to individual
investigators. If so, it must be remembered that the
responsibility remains with the sponsoring
institution. Again the scale of the required resources
will be dependent on the number of clinical trialsundertaken by an institution and their anticipated
pharmacovigilance needs. Based on this evaluation it
may be apparent that the amount of
pharmacovigilance activity anticipated does not
justify a dedicated staff or office. If so, the group
may decide to outsource the pharmacovigilance
service rather than create its own. A number of
organisations are currently able to provide different
aspects of such a service. These vendors include
commercial clinical research organisations, but also
may include public sector groups such as
universities and health service groups, who have
developed robust systems for their own needs and
are now in a position to take on a
pharmacovigilance and/or safety reporting service
provision for others.
6. Implementing training and education of research
staff: The institution must ensure that all relevant
staff are fully aware of the service and are
appropriately trained in its use. Most institutions
will provide researchers with Good Clinical Practice
(GCP) training. Often this will include a generic
pharmacovigilance component, but may lack the
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assess, report and action any Serious Adverse Event
(SAE) report using the local systems and in line with
regulatory requirements. If this is the case additional
education and training will be needed for those staff
involved in CTIMPs and may be provided by the
Pharmacovigilance Office.
7. Maintain oversight: Irrespective of how the service
is provided it is essential that the sponsor institution
retains an oversight function to ensure that their
legal responsibilities for pharmacovigilance are met.
Part of this oversight will be ensuring that any duties
delegated to investigators or third parties are
delivered in a timely fashion, and that the overall
process is kept under review to identify any
problems. Pharmacovigilance SOPs, like all SOPs,
should be reviewed and if necessary revised, on a
regular basis. The pharmacovigilance group will
have a key role in this as well as defining any
developments required in the education and training
of staff.
Implementation of our pharmacovigilance service
The provision of a pharmacovigilance service presents a
number of challenges in the public sector. Our responses
to these challenges have evolved and developed over
the last 8 years and involve several interlinked compo-
nents. Key to our strategy has been establishing a central
Pharmacovigilance Office with dedicated staff and re-
sources to service a wide range of studies sponsored by
our institutions. Organisationally this office sits at the
junction between the NHS and the University and draws
expertise from both. The provision of pharmacovigilance
support requires a mixture of medical, administrative and
IT skills all of which we have concentrated in our
Pharmacovigilance Office. While major elements of safety
reporting in CTIMPs will be delivered by members of in-
vestigative teams in the field we believe that without the
support of a centralised office the pharmacovigilance re-
sponsibilities of the sponsor would not be adequately ful-
filled. The Pharmacovigilance Office has supported a
number of trials since it was established in 2009. We are
currently supporting 10 active CTIMPs for our sponsor
organisation with a further 22 CTIMPs now completed.
This includes a variety of types of trials from single site
to multicentre international trials .In addition the elec-
tronic reporting system has been or is currently used
in a further 13 trials for a number of commercial and
non-commercial sponsors. Our office has a medically
qualified Pharmacovigilance Officer. While not every
organisation may have access to such an individual we
believe that having a medically qualified officer with
clinical trial experience has greatly enhanced our ser-
vice. Other members of the team including theadministrative and IT support staff should also have a
background in clinical research as this will facilitate a
more efficient and user friendly service. It is important
that the Pharmacovigilance Office is not simply viewed
as another bureaucratic hurdle for investigators to leap,
but rather as an approachable and useful service. This
service includes support during the trial, but also ex-
tends to advice before the trial with protocol design and
any study specific reporting requirements, for example,
in studies using Advanced Therapy Investigational
Medicinal Products (ATIMPs) which, although governed
by the same legislation as other clinical trials, have
additional reporting requirements [8]. Support during
a trial includes the review and triaging of all SAE re-
ports received against the information already known of
the expected adverse effects of the IMP in order to iden-
tify any suspected unexpected serious adverse reactions
(SUSARs) which will require expedited reporting to
regulatory authorities. The Pharmacovigilance Office
also supports the preparation and submission of annual
safety reports as required by legislation. Advice is also
provided after the close of the trial regarding the re-
quirements for the archiving of pharmacovigilance doc-
uments in line with regulatory and any study specific
requirements. When planning our office set-up, its loca-
tion, structure and staffing were all taken in to account
to ensure the best use of existing resources and the
future needs of the service.
To streamline the service, an electronic pharma-
covigilance reporting infrastructure was developed. This
incorporates a system for the remote capture of SAE infor-
mation via a secure web portal. Alternatively inves-
tigators can fax reports into a central fax server.
Incorporated into this system are automatic email alerts
to pharmacovigilance staff when an SAE report is re-
ceived facilitating timely review of the event. The data
are held in a central database and the system can pro-
duce individual case safety reports in various layouts,
including the Council for International Organizations of
Medical Sciences format. The database conforms to the
requirements of the relevant European guidance on the
electronic submission of safety reports [9] and can there-
fore facilitate direct reporting to the EudraVigilance
Clinical Trial Module. The system also facilitates the gen-
eration of metrics and line listings that can be used for the
production of reports required for sponsor or manage-
ment oversight, review by Independent Data Monitoring
Committee (IDMC) or for submission of annual safety re-
ports in the format of a Development Safety Update Re-
port (DSUR) [10] to regulatory authorities, research ethics
committees or collaborators.
In line with internal quality management, sponsor or-
ganisation processes and ISO 9001:2008 accreditation we
are continually reviewing and improving the electronic
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tion. Feedback from external audits and inspections has
also led to improvements to the system. The system
has been GCP inspected by the UK Competent Author-
ity on five occasions and is audited by other sponsor or-
ganisations on a regular basis with no major findings.
Our service is underpinned by an education and train-
ing programme that is available to all researchers and
their support staff. Without appropriate training any
pharmacovigilance service will fail. Field staff have to be
aware of the pharmacovigilance office and of the services
it provides and must be familiar with the institution’s
SOPs regarding safety reporting. To achieve this we have
supplemented our standard GCP course with standalone
pharmacovigilance workshops and study specific training
designed specifically for those undertaking CTIMPs.
Conclusions
While our approach has been successful it is not the
only potential solution to the problem. In Glasgow,
as elsewhere, we could have decided to outsource the
pharmacovigilance service to commercial organisations.
This would have been costly and whatever the level of ser-
vice provided, the legislation is clear that the delegation of
tasks does not remove the ultimate responsibility of the
sponsor for the conduct of the clinical trial in accordance
with the applicable legislation. As such, an extensive
oversight mechanism would have had to be established,
which in itself would have had resource implications.
Cost consideration is always a high priority in the public
sector and our decision not to outsource was primarily
a financial one.
Because we are working in a constantly changing regula-
tory landscape we need to be able to respond to new legis-
lation and governance systems. Within the UK we can
expect major changes in the governance of clinical re-
search following the publication of Academy of Medical
Sciences Report [11] and the Proposal for a Regulation
of the European Parliament and of the Council on clin-
ical trials on medicinal products for human use, and
repealing Directive 2001/20/EC [12]. Having a dedicated
pharmacovigilance staff who can keep abreast of these
changes and amend their systems accordingly will en-
sure that the sponsor organisation and investigators are
operating in a fully compliant way.
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